Sugi Predict

Sugi Predict / Targets / NSD3

NSD3

Histone-lysine N-methyltransferase NSD3 · Q9BZ95 · NSD3 on Sugi Atlas →

11,320 patent compounds predicted against NSD3, 9,712 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1641430 SCHEMBL1641430 0.58 10/20
SCHEMBL1920125 SCHEMBL1920125 0.57 8/20
SCHEMBL382916 SCHEMBL382916 0.60 7/20
SCHEMBL1920120 SCHEMBL1920120 0.57 7/20
SCHEMBL97602 SCHEMBL97602 0.56 6/20
SCHEMBL1920123 SCHEMBL1920123 0.56 6/20
SCHEMBL987612 SCHEMBL987612 0.45 6/20
SCHEMBL1422156 SCHEMBL1422156 0.70 5/20
SCHEMBL218588 SCHEMBL218588 0.59 5/20
Adefovir Adefovir (SCHEMBL49373) 0.54 5/20
Adefovir Adefovir (SCHEMBL439995) 0.53 5/20
Adefovir Adefovir (SCHEMBL1262818) 0.50 5/20
SCHEMBL215612 SCHEMBL215612 0.40 5/20
SCHEMBL8148 SCHEMBL8148 0.45 4/20
SCHEMBL366593 SCHEMBL366593 1.00 3/20
SCHEMBL1430299 SCHEMBL1430299 0.65 3/20
SCHEMBL1428350 SCHEMBL1428350 0.63 3/20
SCHEMBL1427882 SCHEMBL1427882 0.62 3/20
SCHEMBL1427845 SCHEMBL1427845 0.58 3/20
SCHEMBL1428062 SCHEMBL1428062 0.57 3/20

Clinical trials — most relevant to NSD3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas PHASE1/PHASE2UNKNOWN
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation PHASE2UNKNOWN
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure PHASE2COMPLETED
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors PHASE1COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid EARLY_PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies nanWITHDRAWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a NSD3 binder may also engage these)

ProteinNameSimilarity
Q6P2L6 — 1.000 Q6P2L6 →
A6QP06 — 0.998 A6QP06 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.997 landscape →
Q8WML3 — 0.996 Q8WML3 →
Q9VGA4 — 0.996 Q9VGA4 →
Q8NDI1 — 0.996 Q8NDI1 →
Q3UG20 — 0.996 Q3UG20 →
Q5HZN1 — 0.995 Q5HZN1 →
Q8C0T5 — 0.995 Q8C0T5 →
Q92613 — 0.995 Q92613 →
Q5JCS6 — 0.995 Q5JCS6 →
Q6NN85 — 0.995 Q6NN85 →
Q8C0C0 — 0.995 Q8C0C0 →
P48193 — 0.994 P48193 →
B2GUY1 — 0.994 B2GUY1 →
A8KBE0 — 0.994 A8KBE0 →
Q9NQW6 — 0.994 Q9NQW6 →
Q8IVE3 — 0.994 Q8IVE3 →
P97868 — 0.994 P97868 →
EPB41 Protein 4.1 0.994 landscape →
Q99PI5 — 0.994 Q99PI5 →
Q6ZPI0 — 0.993 Q6ZPI0 →
Q9JJN2 — 0.993 Q9JJN2 →
KMT5B Histone-lysine N-methyltransferase KMT5B 0.993 landscape →
Q5DTH5 — 0.993 Q5DTH5 →
Q92539 — 0.993 Q92539 →
Q62661 — 0.993 Q62661 →
A4IIJ3 — 0.993 A4IIJ3 →
O95625 — 0.993 O95625 →
Q08AX9 — 0.993 Q08AX9 →